
    
      Part A of the study was an open-label design with morning dosing of SAGE-217 for 7 days and
      included 16 participants, 8 of whom qualified for, and entered, Part B.

      Part B had a double-blind, placebo-controlled, randomized withdrawal design with morning
      dosing for 7 days.

      Part C was an open-label design with morning and evening dosing for 14 days and included a
      different set of 18 participants.

      Parts A and B were stopped early (in advance of the planned sample size).
    
  